Contact Us Today!

617-523-7900

or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?





If you would like a response, please include your contact information.

<< Return to Search Results

Evangelos S. Gragoudas, M.D.

Director, Retina Service
Specialties: Retina
Ophthalmic Oncology
Macular Degeneration Unit
Phone Number: 617-573-3515
Fax: 617-573-3678
Location: Mass. Eye and Ear
243 Charles Street
Boston, MA 02114
Office Hours: Mondays and Tuesdays, 8:30 a.m. - 5:00 p.m.
Language:
Board Certification: Ophthalmology
M.D. Athens National & Kapodistrian University, Athens, Greece
Residency Ophthalmology, Boston University, Boston Medical Center
Fellowship Vitreoretinal Surgery, Mass. Eye and Ear
Teaching Affiliation Charles Edward Whitten Professor of Ophthalmology, Harvard Medical School
Biographical Profile:


An international authority in retinal diseases and intraocular tumors, Dr. Evangelos Gragoudas serves as Director of the Retina Service at Mass. Eye and Ear, a title he has held since 1985. He has helped transform the service into the preeminent academic and clinical service it is today.

Dr. Gragoudas completed his medical training in Athens, Greece and his ophthalmology residency at Boston University School of Medicine. He was a clinical fellow in diabetic retinopathy at the Elliot P. Joslin Research Laboratory at Harvard Medical School, and subsequently a retina fellow under Dr. Charles Schepens at Mass. Eye and Ear. In 1975, Dr. Gragoudas joined the full-time faculty at Mass. Eye and Ear.

Dr. Gragoudas pioneered the use of proton beam irradiation for uveal melanoma, which has been highly successful in safely treating over 15,000 patients to date. He has also worked to further improve diagnosis and treatment for this potentially fatal disease.

With a long-standing interest in retinal disorders, Dr. Gragoudas helped identify vascular-targeting therapies for neovascular diseases of the eye. He was instrumental in developing photodynamic therapy using Visudyne®, which became the first FDA-approved treatment for age-related macular degeneration (AMD). He also was among the first to target vascular endothelial growth factor (VEGF) in the treatment of AMD.

As Director of the Retina Service, Dr. Gragoudas has been instrumental in expanding and improving fellowship programs in the retina subspecialty. Of the clinical retina fellows he trained—100 and counting—many have gone on to pursue leadership roles in medicine, academia, and industry.

Dr. Gragoudas is also the recipient of several major awards and honors, including the esteemed Mildred Weisenfeld Award for Excellence in Ophthalmology from the Associate for Research in Vision and Ophthalmology for his invaluable contributions to the field of ocular oncology and the development of vascular-targeting therapies from numerous eye disorders.

Clinical Interests

Retinal diseases, macular degeneration, intraocular tumors

Research Interests

Retinal diseases, macular degeneration, intraocular tumors

Publications

For a full publication list, please see his CV.

Proton irradiation for peripapillary and parapapillary melanomas. Lane AM, Kim IK, Gragoudas ES. Arch Ophthalmol. 2011 Sep;129(9):1127-30.

Evaluation of tissue interactions with mechanical elements of a transscleral drug delivery device. Cohen SJ, Chan RVP, Keegan M, Andreoli CM, Borenstein JT, Miller JW, Gragoudas ES. Pharmaceutics. 2012 Mar 12;4(1):212-229.

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Daniels AB, Lee JE, MacConaill LE, Pabescandolo E, Hummelen PV, Adams SM, DeAngelis MM, Hahn WC, Gragoudas ES, Harbour W, Garraway LA, Kim IK. Invest. Ophthalmol. Vis. Sci. 2012 Oct 9;53(11): 6991-6996.

Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. Njauw CNJ, Kim I, Piris A, Gabree M, Taylor M, Lane AM, DeAngelis MM, Gragoudas E, Duncan LM, Tsao H. PLOS One. 2012;7(4):e35295.

Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis. Theodoropoulou S, Brodowska K, Kayama M, Morizane Y, Miller JW, Gragoudas ES, Vavvas DG. PLoS One. 2013;8(1):e52852.

View a complete list of publications on pubmed.gov »